Valion Bio outlines end-2026 Entolimod GMP validation target as NIAID funds GI-ARS BLA-enabling work (NASDAQ:VBIO)

Valion Bio (VBIO) Q1 2026 earnings call recap: NIAID-funded Entolimod GI-ARS milestones, GMP validation timeline, cash burn and catalysts—read now.

Read on WOBR AI →